Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs

June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A complete list of Janssen-sponsored abstracts scheduled for presentation during ASCO and EHA is available at the Janssen Oncology Virtual Newsroom. “Through a deliberate scientific focus on deep disease understanding, we continue to advance a diverse, differentiated portfolio and pipeline of targeted therapies and combination regimens in select cancers where unmet medical needs persist,” said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research &Development, LLC. “At this year’s ASCO, we look forward to presenting the latest research from our dedicated scientists on behalf of investigators, study centers and the patients participating in our programs, with a focus on improving the lives of patients diagnosed with cancer and driving toward the elimination of cancer in the future.” “At Jans...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

Authors: Rombauts A, Abelenda-Alonso G, Cuervo G, Gudiol C, Carratalà J Abstract INTRODUCTION: Despite adequate antibiotic coverage, community-acquired pneumonia (CAP) remains a leading cause of hospitalization and mortality worldwide. It induces both a local pulmonary and a systemic inflammatory response, particularly significant in severe cases. The intensity of the dysregulated host response varies from patient to patient and has a negative impact on survival and other outcomes. AREAS COVERED: This comprehensive review summarizes the pathophysiological aspects of the inflammatory response in CAP, brie...
Source: Expert Review of Anti-Infective Therapy - Category: Infectious Diseases Tags: Expert Rev Anti Infect Ther Source Type: research
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Cheng Han, Yinping Zhang, Marc Redmile-Gordon, Huan Deng, Zhenggui Gu, Qiguo Zhao, Fang Wang
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Peter A. Bain, Adrienne Gregg, Alok K. Pandey, Mohana Krishna Reddy Mudiam, Peta A. Neale, Anu Kumar
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Jinquan Chen, Xuan Li, Wei Jia, Shili Shen, Shengjiong Deng, Bohua Ji, Junjun Chang
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part AAuthor(s): Zhongyi Zhang, Wen-Xiong Wang, Nengjian Zheng, Yansheng Cao, Hongwei Xiao, Renguo Zhu, Hui Guan, Huayun Xiao
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Jinsoo Lee, Seong-Jin Choi, Ji-Seong Jeong, Sang Yun Kim, Sang-Hyub Lee, Mi Jin Yang, Seung-Jin Lee, Young-Jun Shin, Kyuhong Lee, Eun Ju Jeong, Sang-Yoon Nam, Wook-Joon Yu
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Publication date: Available online 30 September 2020Source: Journal of Hazardous MaterialsAuthor(s): Anthony Beauvois, Delphine Vantelon, Jacques Jestin, Martine Bouhnik-Le Coz, Charlotte Catrouillet, Valérie Briois, Thomas Bizien, Mélanie Davranche
Source: Journal of Hazardous Materials - Category: Environmental Health Source Type: research
Source: Journal of Toxicology and Environmental Health Part A - Category: Environmental Health Authors: Source Type: research
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
More News: Acetaminophen | Acute Leukemia | Alcoholism | Alimta | Allergy & Immunology | Alopecia | Amyloidosis | Anaphylactic Shock | Anemia | Arrhythmia | Atrial Fibrillation | Back Pain | Biotechnology | Bladder Cancer | Bleeding | Blood Transusion | Brain | Brain Cancers | Breast Cancer | Breast Carcinoma | Breastfed | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Cardiac Arrhythmia | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Chemistry | Chemotherapy | Child Development | Children | China Health | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Obstructive Pulmonary | Chronic Pain | Clinical Trials | Constipation | Corticosteroid Therapy | Cough | Dermatitis | Dermatology | Dexamethasone | Diabetes | Drugs & Pharmacology | Emergency Medicine | Endocrinology | Epilepsy | Epithelial Cancer | European Medicines Agency (EMA) | Fundoscopy | Gastroenterology | Genetics | Hay Fever | Headache | Health Management | Heart | Heart Attack | Heart Disease | Heart Transplant | Hematology | Hemorrhagic Stroke | Hormones | Hypertension | Hypothyroidism | Immunotherapy | Infectious Diseases | Insomnia | Interstitial Lung Disease | Laboratory Medicine | Laryngeal Cancer | Learning | Legislation | Leukemia | Lortab | Lung Cancer | Lung Transplant | Lymphoma | Macroglobulinemia | Magnesium | Marketing | Melanoma | Migraine | Molecular Biology | Myeloma | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Neurology | Neuroscience | Neurosurgery | Non-Small Cell Lung Cancer | Nonmelanoma Skin Cancer | Onycholysis | Opthalmology | Oral Cancer | Organic | Orthopaedics | Pain | Pain Management | Pharmaceuticals | Pneomococcal Vaccine | Pneumonia | Politics | Potassium | Pregnancy | Pregnancy and Breast Cancer | Primary CNS Lymphoma | Profits and Losses | Prostate Cancer | Pulmonary Hypertension | Reflex Sympathetic Dystrophy | Reproduction Medicine | Respiratory Medicine | Revlimid | Science | Serous Carcinoma | Skin | Skin Cancer | Skin Graft | Sodium | Stem Cell Therapy | Stem Cells | Study | Thrombocytopenia | Thyroid | Thyroid Cancer | Toxicology | Transplant Surgery | Transplants | Universities & Medical Training | Vaccines | Velcade | Veterinary Vaccinations | Vitamin A | Waldenstrom's Macroglobulinemia | Warnings | Women